Abstract
Correctly identifying candidate drugs for protein targets is crucial for drug discovery. Despite the importance of this problem for the pharmaceutical industry, chemical screening remains a challenging task, and drug-target misidentification may contribute to failures in drug development. In their recent study, Sauer and colleagues (Holbrook-Smith etal, 2022) demonstrate proof-of-concept for a new way to identify drug-target interactions using high-throughput metabolomics, potentially paving the way towards a universal method for predicting drug-target relationships.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
